- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 07.11. | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say | 3 | Benzinga.com | ||
| 05.11. | TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug | 1 | Investing.com | ||
| 05.11. | Piper Sandler sees big potential for Upstream Bio asthma therapy, Overweight on stock | 2 | Investing.com | ||
| 05.11. | Piper Sandler sieht großes Potenzial für Upstream Bio's Asthma-Therapie, bewertet Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| 05.11. | JPMorgan bullish on Upstream Bio stock, bets on promising asthma drug pipeline | 2 | Investing.com | ||
| 05.11. | JPMorgan optimistisch für Upstream Bio-Aktie, setzt auf vielversprechende Asthma-Medikamenten-Pipeline | 3 | Investing.com Deutsch | ||
| 18.10. | Upstream Bio, Inc. (NASDAQ:UPB) Director Buys $14,025,000.00 in Stock | 1 | MarketBeat | ||
| 15.10. | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 71 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen | |
| 15.10. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.10. | IPO Radar: Cerebras, Upstream Bio and Applied Nutrition | 13 | The Armchair Trader | ||
| 14.10. | Erfolgreicher Börsengang von Upstream Bio | 2 | investrends.ch | ||
| 14.10. | HBM Healthcare Investments AG: Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen | 706 | EQS Group (DE) | HBM Healthcare Investments AG
/ Schlagwort(e): Börsengang
Erfolgreicher Börsengang des HBM-Portfoliounternehmens Upstream Bio; Kapitalaufnahme von USD 255 Millionen
14.10.2024... ► Artikel lesen | |
| 11.10. | Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M | 1 | MedCity News | ||
| 11.10. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.10. | Upstream Bio stock rallies 32% following upsized $255M IPO | 1 | Seeking Alpha | ||
| 11.10. | Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs | 1 | BNN Bloomberg | ||
| 11.10. | Respiratory disorder biotech Upstream Bio prices upsized IPO at $17 high end | 1 | Renaissance Capital | ||
| 11.10. | Upstream Bio Prices Upsized 15M Share IPO at $17/sh | 1 | Investing.com |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,860 | -0,45 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| QIAGEN | 40,065 | +3,15 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Dyne Therapeutics: Leitender Vizepräsident veräußert Aktien im Wert von 77.127 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 18,010 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.
